Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05NFR
|
|||
| Drug Name |
Repotrectinib
|
|||
| Synonyms |
TPX-0005; FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778
Click to Show/Hide
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Approved | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1/2 | [2] | ||
| Company |
Bristol Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H18FN5O2
|
|||
| Canonical SMILES |
CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C
|
|||
| InChI |
1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1
|
|||
| InChIKey |
FIKPXCOQUIZNHB-WDEREUQCSA-N
|
|||
| CAS Number |
CAS 1802220-02-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Ros (ROS1) | Target Info | Inhibitor | [1] |
| Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Endocytosis | ||||
| Apoptosis | ||||
| Neurotrophin signaling pathway | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
| Reactome | Frs2-mediated activation | |||
| ARMS-mediated activation | ||||
| NGF-independant TRKA activation | ||||
| PI3K/AKT activation | ||||
| WikiPathways | MAPK Signaling Pathway | |||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| NGF signalling via TRKA from the plasma membrane | ||||
| Spinal Cord Injury | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218213 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.